Oral Delayed-Release Mesalazine

Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis

1987 • 2,734 citations

British National Formulary

1958 • 2,539 citations

Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee

2004 • 1,770 citations

Mesalamine in the maintenance treatment of Crohn's disease: A meta-analysis adjusted for confounding variables

1997 • 432 citations

Inflammatory Bowel Disease

1996 • 398 citations

A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis

1995 • 313 citations

Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study

1998 • 305 citations

Sulfasalazine Revisited

1993 • 233 citations

Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease

1994 • 215 citations

Oral Mesalamine (Asacol) for Mildly to Moderately Active Ulcerative Colitis

1991 • 211 citations

Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis

1998 • 196 citations

Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis

1988 • 176 citations

Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.

1990 • 171 citations

Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study.

1997 • 167 citations

An Oral Preparation of Mesalamine as Long-Term Maintenance Therapy for Ulcerative Colitis

1996 • 154 citations

A Randomized, Double-Blind, Placebo-Controlled Trial of the Oral Mesalamine (5-ASA) Preparation, Asacol, in the Treatment of Symptomatic Crohn??s Colitis and Ileocolitis

1994 • 149 citations

Renal and Urologic Complications of Inflammatory Bowel Disease

1998 • 139 citations

The mode of action of the aminosalicylates in inflammatory bowel disease

1993 • 138 citations

5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease.

1991 • 136 citations

Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease

1992 • 132 citations

Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid.

1982 • 127 citations

Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth.

1983 • 118 citations

Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis

1995 • 109 citations

Mesalazine-associated interstitial nephritis

1996 • 106 citations

Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate.

1997 • 102 citations

Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis

1992 • 95 citations

Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations.

1992 • 94 citations

Clinical Pharmacokinetics of Drugs Used in the Treatment of Gastrointestinal Diseases (Part I)1

1990 • 81 citations

Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis.

1990 • 81 citations

Peroxynitrite-induced apoptosis in human intestinal epithelial cells is attenuated by mesalamine

1997 • 76 citations

Optimum dose of olsalazine for maintaining remission in ulcerative colitis.

1994 • 75 citations

Topical and systemic availability of 5‐amino‐salicylate: comparisons of three controlled release preparations in man

1990 • 68 citations

Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation

1991 • 67 citations

5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells.

1995 • 65 citations

Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation.

1992 • 63 citations

Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine

1992 • 62 citations

Salicylates for ulcerative colitis—their mode of action

1994 • 61 citations

What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?

1998 • 60 citations

Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid

1991 • 57 citations

A Practical Guide to the Management of Distal Ulcerative Colitis

1998 • 51 citations

5‐amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine

1996 • 49 citations

Management of inflammatory bowel disease.

1998 • 47 citations

Salicylates used in inflammatory bowel disease and colchicine impair interferon-gamma induced HLA-DR expression.

1992 • 46 citations

Lesson of the week: Late onset interstitial nephritis associated with mesalazine treatment

1998 • 45 citations

5-Aminosalicylic acid inhibits the impaired epithelial barrier function induced by gamma interferon.

1996 • 43 citations

Low albumin gradient ascites complicating severe pseudomembranous colitis

1997 • 40 citations

The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine

1985 • 32 citations

Effect of Drugs on Colonic Eicosanoid Accumulation in Active Ulcerative Colitis

1992 • 31 citations

Experience with Eudragit-S-Coated Mesalamine (Asacol) in Inflammatory Bowel Disease

1993 • 30 citations

Disposition of Mesalazine from Mesalazine-Delivering Drugs in Patients with Inflammatory Bowel Disease, with and without Diarrhoea

1992 • 30 citations

New therapeutic agents in the treatment of inflammatory bowel disease

1992 • 29 citations

[Chronic interstitial nephritis and mesalazine: 3 new cases?].

1998 • 28 citations

Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease.

1992 • 25 citations

Mesalamine in pediatric inflammatory bowel disease: A 10-year experience

1996 • 24 citations

Inhibition of red cell membrane lipid peroxidation by sulphasalazine and 5-aminosalicylic acid.

1991 • 23 citations

Systemic availability of 5‐aminosalicylic acid: comparison of delayed release and an azo‐bond preparation

1996 • 22 citations

Is topical therapy necessary in acute distal colitis? Double‐blind comparison of high‐dose oral mesalazine versus steroid enemas in the treatment of active distal ulcerative colitis

1991 • 22 citations

New salicylates as maintenance treatment in ulcerative colitis.

1994 • 20 citations

Inflammatory Bowel Disease

1994 • 17 citations

Guidelines for the treatment of ulcerative colitis in remission

1997 • 17 citations

Modulation of Arachidonic Acid Metabolism by Olsalazine and Other Aminosalicylates in Leukocytes

1991 • 17 citations

Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis?

1992 • 17 citations

Bioavailability of Single and Multiple Doses of Enteric-Coated Mesalamine and Sulphasalazine

1990 • 16 citations

Inflammatory Bowel Disease Management

1997 • 15 citations

Pharmaceutic Development: Mesalazine

1990 • 14 citations

The effect of 5-aminosalicylate and para-cc on the synthesis of prostaglandin E₂and leukotriene B4 in isolated colonic mucosal cells

1996 • 14 citations

New developments in the pharmacotherapy of inflammatory bowel disease

1992 • 13 citations

Modulation of cytokine release from human monocytes by drugs used in the therapy of inflammatory bowel diseases.

1995 • 13 citations

Mesalazine release from coated tablets: effect of dietary fibre.

1991 • 12 citations

Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease

1998 • 12 citations

Absorption of Oral Mesalazine-Containing Preparations and the Influence of Famotidine on the Absorption

1990 • 10 citations

Composition of the efficacy and safety of sulphasalazine and mesalazines in the maintenance treatment of ulcerative colitis: a meta-analysis

1993 • 9 citations

Maintenance treatment with balsalazide provides more effective control of nocturnal symptoms of ulcerative colitis (UC) than delayed-release mesalazine

1998 • 6 citations

Recent developments in inflammatory bowel disease therapy

1997 • 4 citations

Deleted Work

1955 • 0 citations